Results 111 to 120 of about 15,738 (210)

Efficacy of up to 4 years of tralokinumab in adults with moderate‐to‐severe atopic dermatitis

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 5, Page 876-886, May 2026.
AD is a relapsing and remitting skin disease often requiring long‐term treatment. We assessed the long‐term efficacy of tralokinumab in adults with moderate‐to‐severe AD consistently treated for up to 4 years. Treatment with tralokinumab plus optional TCS/TCI provided substantial improvements in AD signs and symptoms, and these improvements were ...
Melinda Gooderham   +13 more
wiley   +1 more source

Ocular Allergy Within the Framework of the EAACI Nomenclature of Allergic Diseases and Hypersensitivity Reactions. [PDF]

open access: yesAllergy Asthma Immunol Res
Bogacka E   +7 more
europepmc   +1 more source

Global Perspectives on Therapy for Noninfectious Conjunctival Hyperemia: A Narrative Review. [PDF]

open access: yesOphthalmol Ther
Toyos M   +9 more
europepmc   +1 more source

Sexual Dimorphism in Allergic and Mast Cell-Associated Diseases. [PDF]

open access: yesClin Rev Allergy Immunol
Kotha A   +8 more
europepmc   +1 more source

Clinical profile of ocular allergy and its impact on quality of life in Brazilian children and adolescents. [PDF]

open access: yesRev Paul Pediatr
Marino LM   +6 more
europepmc   +1 more source

IL-18 receptor axis in allergic conjunctivitis: a multi-omics study. [PDF]

open access: yesFront Immunol
Yuan L   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy